VIDEO: Intravitreal gene therapy for wet AMD demonstrates positive results
Key takeaways:
- The phase 1/2 PRISM trial evaluated the safety, efficacy and durability of 4D-150.
- Participants experienced stable visual acuity and improvement in central subfield thickness.
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Arshad M. Khanani, MD, MA, discusses the PRISM trial evaluating 4D-150 intravitreal gene therapy for the treatment of wet age-related macular degeneration.
“The idea is that we have seen inflammation with intravitreal gene therapy in the past, so the goal is, with lower doses and adequate prophylaxis, we wanted to see if we could have good safety with a one-time gene therapy injection,” he said.
According to Khanani, the dual-transgene intravitreal gene therapy demonstrated positive results in both the low-dose and high-dose cohorts.
Collapse
Khanani A, et al. Interim results for the phase 1/2 PRISM trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.
Read more about